GlobeNewswire

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors

Share

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method

ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization.

Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolled in the clinical trial.

“Our goal for the trial is to determine safety and tolerability of IP-001 in patients with thermally ablated solid tumors and to assess potential enhanced immunological effects of intratumoral injection of IP-001 as an adjunct to tumor ablation,” said Tomas Hode, PhD, Co-Founder and Chief Innovation Officer of Immunophotonics, Inc. “We look forward to this collaboration with CLS and are excited to learn more about the potential synergistic effects between the two technologies.” 

“CLS is tremendously excited with this opportunity to deliver our TRANBERG® technology and imILT in this clinical trial and to be part of the development of a new cancer treatment,” said Lars-Erik Eriksson, CEO of CLS. “The trial will provide CLS with extensive safety data and experience from new users, as well as information of the potential for imILT in conjunction with IP-001 injection.”

About Clinical Laserthermia Systems
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund, Sweden and has a subsidiary in Berlin, Germany and Irvine, CA, USA, is listed in Nasdaq First North under the ticker CLS B. Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250, E-mail: ca@vhcorp.se. Further information is available on www.clinicallaser.se.

About Immunophotonics
Immunophotonics, Inc., a private biotechnology company focused on the burgeoning field of Interventional Immuno-Oncology™, is developing drugs to improve outcomes of interventional oncology procedures, such as tumor ablation and ablative radiation. Their lead compound, a polymer (IP-001), is designed to be injected intratumorally immediately after an interventional procedure, such as tumor ablation, which in turn may induce a polyclonal T cell response against the cancer. The approach is an attractive way for the surgeon or interventional radiologist to potentially both gain better control of tumor margins (and local recurrence) in locally ablated tumors, as well as to elevate an otherwise-local interventional procedure into an immunotherapy for cancer. This, in turn, may act synergistically with traditional immunotherapies administered by the medical oncologist. For more info, visit: www.immunophotonics.com.

The TRANBERG®|Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA).

Media Contact for Clinical Laserthermia Systems AB:
TopSpin Communications
Joe Waldygo
P: +1 480-363-8774
E: joe@topspinpr.com

Contact Information
Clinical Laserthermia Systems AB:
Lars-Erik Eriksson, CEO
P: +46 70 290 33 00
E: lee@clinicallaser.se

Contact Information
Immunophotonics, Inc.
Alex Hurst
info@immunophotonics.com

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Hiab secures its biggest ever commercial order18.7.2019 13:30:00 CESTPress release

CARGOTEC CORPORATION, PRESS RELEASE, 18 JULY 2019 AT 2:30 PM EEST Hiab, part of Cargotec, has signed a record-breaking agreement to supply MOFFETT M8 55.4 NX truck mounted forklifts with five year ProCare Essential service contracts and equipped with HiConnect for each unit, with one of the largest home improvement chains in the USA. The total order value is over EUR 60 million. In the second quarter, EUR 31 million was booked in the order entry with EUR 29 million booked for the third quarter. This is Hiab’s largest ever commercial deal and ProCare contract agreement, as well as the biggest single order for the Truck Mounted Forklift Business Line. Deliveries are expected to start in the third quarter 2019 and continue until May 2020. When complete, the customer will have updated a significant portion of their fleet with new connected equipment. This will enable them to collect data from a substantial part of the fleet to improve productivity, safety and get service alerts based on ac

Sweden to issue green bonds by 202018.7.2019 13:10:00 CESTPress release

The Swedish National Debt Office was tasked today by the Government with carrying out an issue of green bonds in 2020 at the latest. The first step will be to set up a framework for the green bonds, which will fund budget expenditure on sustainable investments and projects. "We are fully committed to implementing this assignment in an effective and transparent way. The effects of the climate and environmental measures that are funded by the State’s green bonds should be easy for investors to follow and evaluate", says Debt Office Director General Hans Lindblad. The assignment includes working together with the Government Offices to set up the ‘green framework’, which includes defining the expenditure items in the budget that will be funded by the green bonds. The Debt Office shall also analyze how to carry out the issue in an optimal way within the management of central government debt. The issuance volume shall, according to the assignment, comply with the objective of the debt manage

Riksgälden ska ge ut gröna obligationer senast 202018.7.2019 13:10:00 CESTPressemelding

Riksgälden har fått i uppdrag av regeringen att senast under 2020 genomföra en emission av statliga gröna obligationer, det vill säga obligationer som finansierar utgiftsposter i statens budget som går till hållbara investeringar och projekt. Nu inleds arbetet med att ta fram ett ramverk för de statliga gröna obligationerna. – Vi tar oss an uppdraget med full kraft och inleder nu vårt förberedande arbete för att genomföra det på ett effektivt och transparent sätt. Som investerare ska man tydligt kunna följa och utvärdera de miljö- och klimatsatsningar som finansierats med de statliga gröna obligationerna, säger riksgäldsdirektör Hans Lindblad. Uppdraget från regeringen omfattar att samverka med Regeringskansliet för att utarbeta det så kallade gröna ramverket. I ramverket ska det bland annat definieras vilka utgiftsposter i statens budget som ska finansieras genom de gröna obligationerna. Riksgälden ska också analysera hur emissionen ska genomföras på bästa sätt inom ramen för statssku

Cargotec’s January–June 2019 half year financial report: Good progress in Hiab and Kalmar18.7.2019 13:00:00 CESTPress release

CARGOTEC CORPORATION, 2019 HALF YEAR FINANCIAL REPORT, 18 JULY 2019 AT 2.00 PM EEST Cargotec’s January–June 2019 half year financial report: Good progress in Hiab and Kalmar Strong profit growth in Kalmar Record high operating profit in Hiab Weak result in MacGregor April–June 2019 in brief: Operating profit increased Orders received decreased by 11 percent and totalled EUR 872 (981) million. Comparison period included a single order for Kalmar worth around EUR 80 million. Order book amounted to EUR 2,072 (31 Dec 2018: 1,995) million at the end of the period. Sales increased by 12 percent and totalled EUR 911 (816) million. Service sales increased by 5 percent and totalled EUR 259 (247) million. Service and software sales represented 33 (34) percent of consolidated sales. Operating profit was EUR 53.0 (21.3) million, representing 5.8 (2.6) percent of sales. Comparable operating profit increased by 12 percent and amounted to EUR 64.3 (57.2) million, representing 7.1 (7.0) percent of sal

Orange Belgium launches Love Duo, the mobile and fixed internet pack intended for cord-cutters18.7.2019 08:52:00 CESTPress release

Press release Brussels, 18 July 2019 Orange Belgium launches Love Duo, the mobile and fixed internet pack intended for cord-cutters In keeping with its bold challenger role, Orange Belgium is once again offering consumers a choice. Henceforth they will only pay for the services they really need. Love Duo is a mobile subscription à la carte, to which is added the fixed internet access for packs costing between 42 and 64 euros, depending on the desired volumes of voice and data. After launching the first unlimited mobile subscription in Belgium, Orange Belgium went and did it again with the first unlimited convergent offer. Since its launch, the Love offer has succeeded in attracting over 200,000 customers, upending the convergent offers market in its wake. Orange Belgium is now attacking one of the main nodal points of the Belgian telecom market by launching Love Duo, a pack including only a mobile subscription and ultrafast and unlimited fixed internet. An offer intended first and fore

Statkraft AS: Resultat for andre kvartal 201918.7.2019 08:00:00 CESTPressemelding

Markedsaktiviteter og høyere kraftproduksjon løftet kvartalsresultatet (Oslo, 18. juli 2019) Statkraft oppnådde et underliggende driftsresultat på 2619 millioner kroner i andre kvartal. Dette var en økning på 1190 millioner kroner fra tilsvarende periode i fjor. Økningen skyldtes hovedsakelig forbedret resultat fra Markedsoperasjoner og høyere kraftproduksjon. Gjennomsnittlig nordisk systempris i kvartalet var 35,6 EUR/MWh, en nedgang på 9 prosent sammenlignet med samme kvartal i 2018. Statkrafts totale kraftproduksjon ble 12,3 TWh, en økning på 0,9 TWh. Resultat etter skatt endte på 2123 millioner kroner. Dette er en økning på 1852 millioner kroner. I første halvår oppnådde Statkraft et underliggende driftsresultat på 9049 millioner kroner, en forbedring på 1659 millioner kroner sammenlignet med samme periode i 2018. Hoveddriverne for forbedringen var høyere bidrag fra handelsaktivitetene i segmentet Markedsoperasjoner. Resultat etter skatt for første halvår endte på 6874 million kron